DPP4,一个潜在的瘤生物标志物,和瘤治疗点:审查
Lu Sun1, Yuhui Ma1, Chenchen Geng1
1Department of Ultrasound, Qilu Hospital of Shandong University (Qingdao), Qingdao, 266035, China.
Molecular biology reports
|January 17, 2025
概括
滴基酶4 (DPP4) 是一种关键酶,与促进癌症有关. 了解 DPP4 的理解
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 二基酶4 (DPP4) 是一种血清蛋白酶,具有多种生理作用,包括炎症和细胞调节.
- 越来越多地认识到DPP4在促进癌症中的参与,尽管其在不同类型的瘤中的特定功能仍然不清楚.
研究的目的:
- 审查二乙酶4 (DPP4) 的结构.
- 总结最近关于DPP4表达和常见瘤机制的研究.
- 讨论DPP4抑制剂在癌症治疗中的治疗潜力.
主要方法:
- 关于DPP的现有研究的文献综述4.
- 在各种瘤类型中分析DPP4表达模式.
- 对潜在的分子机制的探索,这些机制是DPP4在瘤发生中的作用的基础.
主要成果:
- 在不同癌症类型中,DPP4的表达有所不同,这表明了特定环境的作用.
- 通过多种机制,DPP4有助于促进癌症.
- 作为一种治疗策略,DPP4抑制剂显示出有前途.
结论:
- DPP4是癌症治疗的潜在药物标.
- 需要进一步的研究才能充分阐明DPP4在瘤中的调节机制.
- 了解DPP4的作用对于开发有效的癌症治疗至关重要.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295